查看文章

This study evaluates the generalizability of data from Ocrelizumab phase 3 clinical trials and its effectiveness in a real-world setting of an Arab population within a rapidly developing country such as Qatar.

Ocrelizumab was FDA approved in 2017 as the newest drug for the treatment of both relapsing-remitting (RRMS) and primary progressive multiple sclerosis (PPMS). OPERA I/II, the major clinical trials, for RRMS shows it is highly efficacious in controlling clinical and radiological activity with a good safety profile and generalizability.

In this retrospective longitudinal cohort study patients were between 18–75 years old; had a confirmed MS; started Ocrelizumab after physician approval; received minimum 3 infusions and 24 months follow up.

Clinical relapses, baseline and monitoring imaging and adverse events.

Demographics, disability …